India’s drug regulator has given permission to Bharat Biotech to conduct phase-3 clinical trial for its intranasal Covid vaccine as booster dose on participants who have been previously inoculated with SARS-CoV 2 vaccines. India is yet to approve the use of intranasal Covid-19 vaccine BBV154 developed by the Hyderabad-based company. 

Drugs Controller General of India (DCGI) on January 27 gave the nod to Bharat Biotech to conduct phase-3 randomised multi-centric clinical study to evaluate immunogenecity and safety of its intranasal vaccine as booster dose on participants who have been previously vaccinated with Covid-19 vaccines approved under the New Drugs & Clinical Trials Rules, 2019. According to official sources, the trial would be conducted at five sites, including AIIMS Delhi.